Evidence map›Paper›PMID 41884650›Full record

ArticleGastroenterology & hepatology2026

Redefining Early Intervention and the Window of Opportunity in Crohn's Disease.

Gülden Bilican, Samuel Majna, Tobi Dairo, Megha Bhandari, Mohmmed Tauseef Sharip, Nurulamin M Noor

Abstract read
In one paragraph

Article in Gastroenterology & hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gülden BilicanDepartment of Gastroenterology, Gazi University School of Medicine, Ankara, Türkiye.
Samuel MajnaDepartment of Gastroenterology, Bezrucova Clinic, Bratislava, Slovakia.
Tobi DairoDepartment of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.
Megha BhandariDepartment of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Mohmmed Tauseef SharipDepartment of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Nurulamin M NoorDepartment of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Crohn's disease is a chronic, progressive inflammatory bowel condition characterized by unpredictable episodes of flare and remission. Inflammation that is not controlled, and even in instances when inflammation is controlled, often has a substantial impact on quality of life for individuals with Crohn's disease, affecting relationships, education, and work productivity. The concept of a therapeutic window of opportunity has long been recognized as a period within which to maximize effectiveness of interventions and potentially modify the course of disease. However, there has been considerable uncertainty over the years on when the window of opportunity is, or how early should early effective intervention be in Crohn's disease. In recent years, there has been a growing body of evidence supporting early intervention to maximize benefit and improve outcomes for patients, and several seminal studies have provided insights into the true window of opportunity. This article summarizes the latest evidence for early effective intervention and considers when to intervene in the therapeutic window of opportunity to maximize outcomes and quality of life for people living with Crohn's disease.

Indexed as

Crohn’s diseaseearly interventioninflammatory bowel diseasetherapeutic window of opportunity

Identifiers

PMID41884650
PMCPMC13011864

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.